Renal complications in multiple myeloma and related disorders: Survivorship care plan of the international myeloma foundation nurse leadership board

Clinical Journal of Oncology Nursing

Volumn 15, Issue SUPPL., 2011, Pages 66-76

  Faiman, Beth M ^a   Mangan, Patricia ^b   Spong, Jacy ^c   Tariman, Joseph D ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MAYO CLINIC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053071357     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/11.CJON.S1.66-76     Document Type: Article

References (41)

1. Attal, M., Cristini, C., Marit, G., Caillot, T., Facon, C., Hullin, P., Harousseau, J.L. (2010). Lenalidomide maintenance after transplantation for myeloma. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=41503
2. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Bataille, R. (2002). Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome. Retrieved from http://www.cancereducation.com/CancerSysPagesNB/abstracts/mmrf/31/AAVW1.pdf
3. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Bataille, R. (2003). Single versus double autologous stem cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495-2502.
4. Attal, M., Harousseau, J.L., Lewraz, S., Doven, C., Hulin, C., Benboubker, L., Facon, T. (2006). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108, 3289-3294.
5. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Bataille, R. (1996). A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91-97.
6. Blade, J., Fernandez-Llama, P., Bosch, F., Montoliu, J., Lens, X.M., Montoto, S., Monserrat, E. (1998). Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Archives of Internal Medicine, 158, 1889-1893. doi:10.1001/archinte.158.17.1889
7. Blade, J., & Rosinol, L. (2005). Renal, hematologic, and infectious complications in multiple myeloma. Best Practice and Research. Clinical Haematology, 18, 635-652. doi:10.1016/j.beha.2005.01.013
8. Blade, J., Sonneveld, P., San Miguel, J.F., Sutherland, H.J., Hajek, R., Nagler, A., DOXYL-MMY-3001 Study Investigators. (2008). Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment. Clinical Lymphoma and Myeloma, 8, 352-355. doi:10.3816/CLM.2008.n.051
9. Bradwell, A.R., Harding, S.J., Fourrier, N.J., Wallis G.L.F., Drayson, M.T., Carr-Smith, H.D., & Mead, G.P. (2009). Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clinical Chemistry, 55, 1646-1655. doi:10.1373/clinchem.2009.123828
10. Brater, D.C. (1999). Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus of cyclooxygenase-2-selective inhibition. AJN, 107, 65-70.
11. Bridoux, F., Sirac, C., Hugue, V., Decourt, C., Thierry, A., Quellard, N., Touchard, G. (2005). Fanconi's Syndrome induced by a monoclonal V3 light chain in Waldenström's macroglobulinemia. American Journal of Kidney Diseases, 45, 749-757. doi:10.1053/j.ajkd.2004.12.020
12. ® (melphalan) [Product information]. Summit, NJ: Author
13. ® (lenalidomide) [Product information]. Warren, NJ: Author.
14. ® (thalidomide) [Product information]. Summit, NJ: Author.
15. Chanan-Khan, A.A., Kaufman, J.L., Mehta, J., Richardson, P.G., Miller, K.C., Lonial, S., Singhal, S. (2007). Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood, 109, 2604-2606. doi:10.1182/blood-2006-09-046409
16. Chanan-Khan, A.A., Miller, K.C., Musial, L., Padmanabhan, S., Yu, J., Ailawadhi, S., Czuczman, M.S. (2009). Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial. Leukemia and Lymphoma, 50, 1096-1101. doi:10.1080/10428190902912460
17. Clark, W.F., & Garg, A.X. (2008). Plasma exchange for myeloma kidney: Cast(s) away? Kidney International, 73, 1211-1213. doi:10.1038/ki.2008.117
18. Clark, W.F., Stewart, A.K., Rock, G.A., Sternbach, M., Sutton, D.M., Barrett, B.J., the Canadian Apheresis Group. (2005). Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Annals of Internal Medicine, 143, 777-784.
19. Cook, R. (2008). Economic and clinical impact of multiple myeloma to managed care. Journal of Managed Care Pharmacy, 14(7, Suppl.), S19-S25.
20. Coward, R.A. (1989). The cost of chronic dialysis in multiple myeloma. Postgraduate Medicine Journal, 65, 302-306. doi:10.1136/pgmj.65.763.302
21. Dimopoulos, M., Alegre, A., Stadtmauer, E.A., Goldschmidt, H., Zonder, J.A., de Castro, C.M., Weber, D.M. (2010). The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer, 116, 3807-3814. doi:10.1200/JCO.2010.30.8791
22. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., the Multiple Myeloma (010) Study nvestigators. (2007). Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132. doi:10.1056/NEJMoa070594
23. McCarthy, P.L., Owzar, K., Anderson, K.C., Hofmeister, C.C., & Hurd, D.D. (2010). Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM). Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=43089
24. Miceli, T., Colson, K., Faiman, B., Miller, K., Tariman, J.D., & the International Myeloma Foundation Nurse Leadership Board. (2011). Maintaining bone health in patients with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(4, Supp.), 9-23.
25. ® (bortezomib) [Product information]. Cambridge, MA: Author.
26. National Comprehensive Cancer Network. (2010a). Clinical Practice Guidelines in Oncology™: Cancer- and chemotherapy-induced anemia [v.1.2011]. Retrieved from http://www.nccn.org/profes sionals/physician_gls/f_guidelines.asp
27. National Comprehensive Cancer Network. (2010b). Clinical Practice Guidelines in Oncology™: Multiple myeloma [v.1.2011]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guide lines.asp
28. National Kidney Foundation. (2010). About chronic kidney disease. Retrieved from http://www.kidney.org/professionals/KLS/ aboutCKD.cfm
29. O'Seaghdha, C.M., Perkovic, V., Lam, T.H., McGinn, S., Barzi, F., Gu, D.F., the Asia Pacific Cohort Studies Collaboration. (2009). Blood pressure is a major risk factor for renal death: An analysis of 560 352 participants from the Asia-Pacific region. Hypertension, 54, 509-515. doi:10.1161/HYPERTENSIONAHA.108.128413
30. Palumbo, A., & Rajkumar, S.V. (2009). Treatment of newly diagnosed myeloma. Leukemia, 23, 449-456. doi:10.1038/leu.2008.325
31. Penfield, J.G. (2006). Multiple myeloma in end-stage renal disease. Seminars in Dialysis, 19, 329-334.
32. Perazella, M.A., & Markowitz, G.S. (2008). Bisphosphonate nephrotoxicity. Kidney International, 74, 1385-1393.
33. Rajkumar, S.V., & Dispenzieri, A. (2008). Multiple myeloma. In M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.E. Kastan, & W.G. McKenna (Eds.), Abeloff clinical oncology (4th ed., pp. 2323-2352). Philadelphia, PA: W.B. Saunders.
34. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.V., the Eastern Cooperative Oncology Group. (2010). Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed myeloma: An open-label randomized controlled trial. Lancet Oncology, 11, 29-37. doi:10.1016/ S1470-2045(09)70284-0
35. Rajkumar, S.V., & Kyle, R.A. (2005). Multiple myeloma: Diagnosis and treatment. Mayo Clinic Proceedings, 80, 1371-1382. doi:10.4065/80.10.1371
36. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., the VISTA Trial Investigators. (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917. doi:10.1056/NEJMoa0801479
37. Taheri, D., Chehrei, A., Fesharakizadeh, M., Seyrafean, S., Shahidi, S., & Emami, A. (2007). Recurrent multiple myeloma following renal transplantation: A case report. Transplantation Proceedings, 39, 1063-1065. doi:10.1016/j.transproceed.2007.02.015
38. Tariman, J., & Faiman, B. (2011). Multiple myeloma. In C.H. Yarbro, D. Wujcik, & B.H. Gobel (Eds.), Cancer nursing: Principles and practice (7th ed., pp. 1513-1545). Boston, MA: Jones and Bartlett.
39. Unger, E.F., Thompson, A.M., Blank, M.J., & Temple, R. (2010). Erythropoiesis-stimulating agents-Time for a re-evaluation. New England Journal of Medicine, 362, 189-192. doi:10.1056/ NEJMp0912328
40. van Agthoven, M., Segeren, C.M., Buijt, I., Uyl-de Groot, C.A., van der Holt, B., Lokhorst, H.M., & Sonneveld, P. (2004). A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem cell rescue in newly diagnosed patients with stage II/III multiple myeloma: A prospective randomised phase III study. European Journal of Cancer, 40, 1159-1169. doi:10.1016/j.ejca.2004.01.019
41. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., the Multiple Myeloma (009) Study Investigators. (2007). Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133-2142. doi:10.1056/NEJMoa 070596